AEZ started at a dollar though. They both dropped about the same percentage already. AEZ's drug didn't fail. The FDA just asked for another trial.
I'm not sure about your reasoning. Regardless of the market cap prior to the offering, the offering price was at 2.75. That sets the valuation of the company as far as I'm concerned (~182 million market cap). I think the stock stayed above that value ($2.75) because the market thinks CYTR is worth more than 182 million. I could be wrong.
I have to say I was dissappointed when Osiris sold off Prochymal. In hindsight it was a good idea. Sanofi bought out Genzyme and then basically bailed on Prochymal. At the time, the wound care products looked like they had more legs and easier FDA approval process. I thought Prochymal had a bigger revenue potential but riskier path to approval (there was some c-reactive protein data that was discouraging as well). Anyway, Osiris still has a great revenue potential with Grafix as well as the other regenerative medicine products. Oz, would you like to comment on Osiris past and present future? The diabetic foot ulcer market alone is projected to grow to 1.5 billion by 2017 (just a google search). So with 20% market share and at 10 x sales OSIR gets pretty close to triple digits. Well good luck to all.
They probably won't need 300 patients. The current plan for 40 patients may be enough for approval. Remember this is brain cancer not diabetes.
Just did a google search. Looks like a pretty high percentage is EGFR positive. I'm not sure about Aldo, but the two therapies could probably be used in combination. THLD's drug is currently being tested in combination with dox.
Eur J Surg Oncol. 2006 May;32(4):466-8. Epub 2006 Mar 7.
Expression of HER1/EGFR protein in human soft tissue sarcomas.
Yang JL1, Hannan MT, Russell PJ, Crowe PJ.
To measure epidermal growth factor receptor (HER1/EGFR) expression in a range of soft tissue sarcoma (STS) patient samples.
HER1/EGFR expression was examined by immunohistochemistry in archival tissues of 46 STS patients.
HER1/EGFR was positively expressed in 36/46 of STS samples distributed among different histological types. The levels of HER1/EGFR in STS tumour tissues in positive samples were higher compared to those in nearby normal tissues.
HER1/EGFR is significantly expressed in soft tissue sarcomas, which is a finding reflected in other series. The significance of this finding for targeted therapy is as yet unknown.
THLD's drug is an EGFR inhibitor. There are a few of them in clinical trials. THLD drug may have some advantages over the other EGFR because it is a pro-drug that gets release in certain tumor environments. THLD drug is only going to be efficacious in EGFR positive tumors with low oxygen where as Aldox is "active" in all tumors with low pH. PFS for THLD drug was not impressive but OS in STS looked good. Just looking at the molecule it looks pretty scary but dox doesn't look like gumdrops either.